- LakeShore Biopharma's ordinary shares and warrants were suspended from trading on The Nasdaq Capital Market effective **September 22, 2025**.  **[1946399_0001213900-25-089823_ea025820501ex99-1_lakeshore.htm:0]** 
- The company's ordinary shares and warrants are expected to commence trading on the **OTC Pink Open Market** under the symbols **"LSBCF"** and **"LSBWF"** on **September 22, 2025**.  **[1946399_0001213900-25-089823_ea025820501ex99-1_lakeshore.htm:0]** 
- The delisting from Nasdaq was due to non-compliance with the **minimum bid price requirement** and ineligibility for a compliance period following a prior reverse stock split.  **[1946399_0001213900-25-089823_ea025820501ex99-1_lakeshore.htm:0]** 
- LakeShore Biopharma will remain a reporting company with the U.S. Securities and Exchange Commission despite the transition to the OTC Market.  **[1946399_0001213900-25-089823_ea025820501ex99-1_lakeshore.htm:0]**

LakeShore Biopharma Transitions to OTC Market Following Nasdaq Delisting

- LakeShore Biopharma's (LSB) ordinary shares and warrants were suspended from trading on The Nasdaq Capital Market and began trading on the **OTC Pink Open Market** under the symbols **"LSBCF"** and **"LSBWF"** on **September 22, 2025**.  **[1946399_20250922CN79889:0]** 
- The delisting followed a Nasdaq determination on September 11, 2025, due to the company's non-compliance with the minimum bid price requirement and ineligibility for a compliance period after a prior reverse stock split.  **[1946399_20250922CN79889:0]** 
- The transition to the OTC Market **does not change LakeShore Biopharma's business operations**, and the company remains a reporting entity with the U.S. Securities and Exchange Commission.  **[1946399_20250922CN79889:0]**

LakeShore Biopharma Shares Transition to OTC Market Following Nasdaq Delisting

- LakeShore Biopharma (LSB) received a delisting determination letter from Nasdaq on **September 11, 2025**, for non-compliance with the Bid Price Rule, as its closing bid price was below **$1.00 per share** for **30 consecutive business days**.  **[1946399_0001213900-25-087068_ea025715101ex99-1_lakeshore.htm:0]** 
- The company is ineligible for the standard 180-day compliance period due to a **10-for-1 reverse stock split** effected on **October 1, 2024**.  **[1946399_0001213900-25-087068_ea025715101ex99-1_lakeshore.htm:0]** 
- Nasdaq has determined to delist LSB's securities, with trading suspension scheduled for the opening of business on **September 22, 2025**, unless the company requests an appeal.  **[1946399_0001213900-25-087068_ea025715101ex99-1_lakeshore.htm:0]** 
- LSB has until **September 18, 2025**, to request a hearing before a Nasdaq Hearings Panel, but there is no assurance that an appeal would be successful or that the company will regain compliance.  **[1946399_0001213900-25-087068_ea025715101ex99-1_lakeshore.htm:0]**

Company not found (LSB)